Beijing Shangdi New Century Biological Medicine Research Institute

Beijing Shangdi New Century Biological Medicine Research Institute is a Chinese biotechnology entity primarily focused on the research and development of human vaccines. The institute gained significant international recognition for its early work on the world's first SARS vaccine candidate to enter clinical trials in the early 2000s. It is closely associated with the leadership of Sinovac Biotech, serving as a foundational research arm and shareholder in the development of various viral vaccines. The organization specializes in inactivated vaccine technology and has historically contributed to public health responses against emerging infectious diseases.